Your session is about to expire
← Back to Search
Small Molecule
JNJ-67484703 for Rheumatoid Arthritis
Phase 1
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Summary
This trial is testing JNJ-67484703, a specially designed antibody, in people with active rheumatoid arthritis. The treatment aims to help the immune system stop attacking its own tissues, which can reduce inflammation and symptoms.
Eligible Conditions
- Rheumatoid Arthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Participants with Abnormalities in Laboratory Parameters
Percentage of Participants with Abnormalities in Physical Examination
Percentage of Participants with Abnormalities in Vital Signs
+3 moreSecondary study objectives
Change from Baseline in Disease Activity Index Score 28 using C-reactive Protein (DAS28-CRP) at Week 12
Change in Magnitude and Duration of Cell Surface Expression Level of Receptors
Change in Number of T-lymphocyte Populations in Blood
+5 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: JNJ-67484703Experimental Treatment1 Intervention
Participants will receive multiple doses of JNJ-67484703.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive multiple doses of placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-67484703
2021
Completed Phase 1
~50
Find a Location
Who is running the clinical trial?
Janssen Research & Development, LLCLead Sponsor
1,004 Previous Clinical Trials
6,402,763 Total Patients Enrolled
5 Trials studying Rheumatoid Arthritis
678 Patients Enrolled for Rheumatoid Arthritis
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
770 Previous Clinical Trials
3,978,503 Total Patients Enrolled
2 Trials studying Rheumatoid Arthritis
278 Patients Enrolled for Rheumatoid Arthritis
Share this study with friends
Copy Link
Messenger